Fig. 3.

CTD regulates the AKT-MDM2-p53 signaling pathway. a Cancer signaling Phosphor Antibody Microarray was performed in HCT-15 cells and followed the CTD (10 μM) treated and untreated cells. b The microarray results were validated by western blotting. c CTD binds with AKT in the CRC cells. d HCT-116 cells were treated with or without 10 μM of CTD for 24 h. Cell lysates were immunoprecipitated with 1 μg of AKT and/or MDM2 antibodies, and binding activities were analyzed by western blot analysis. e The signaling pathway of AKT–MDM2–p53 was examined by the western blot analysis after CTD treatment for 24 h at different concentrations (0, 2.5, 5, or 10 μM) in the CRC cells